Liquidia Technologies, Inc. (LQDA) News

Liquidia Technologies, Inc. (LQDA)

Today's Latest Price: $5.05 USD

0.21 (4.34%)

Updated Sep 25 4:00pm

Add LQDA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter LQDA News Items

LQDA News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest LQDA News From Around the Web

Below are the latest news stories about Liquidia Technologies Inc that investors may wish to consider to help them evaluate LQDA as an investment opportunity.

When Will Liquidia Technologies, Inc. (NASDAQ:LQDA) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at Liquidia Technologies...

Yahoo | September 14, 2020

Liquidia Technologies nabs new U.S. patent covering inhaled dry powder treprostinil

The USPTO has issued a Notice of Allowance to Liquidia Technologies (LQDA) for patent application No. 16/099,135, covering methods of treating patients with pulmonary hypertension through the inhalation of dry powder treprostinil.The drug candidate is currently under review with FDA for the treatment of pulmonary arterial hypertension.The patent is expected...

Seeking Alpha | August 28, 2020

Liquidia Announces Chief Financial Officer Transition

Steven Bariahtaris Appointed Interim Chief Financial OfficerRESEARCH TRIANGLE PARK, N.C., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced Steven Bariahtaris has been appointed interim Chief Financial Officer (CFO), effective immediately. He succeeds Richard Katz, M.D. who has resigned from his role at Liquidia in order to pursue other opportunities. Liquidia has engaged Spencer Stuart, a global executive search and leadership advisory firm, to conduct the search for a permanent successor. “Steve is a talented and proven leader who is known for his strategic insights, financial expertise ...

Yahoo | August 20, 2020

Liquidia Technologies (LQDA) Investor Presentation - Slideshow

The following slide deck was published by Liquidia Technologies, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 13, 2020

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time. A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.About LiquidiaLiquidia is a late-stage clinical biopharmaceutical company focused on the development and commercial...

Yahoo | August 5, 2020

Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting

New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced that exploratory endpoint data from the INSPIRE study evaluating LIQ861 in patients with pulmonary arterial hypertension (PAH) was released today through a virtual presentation at the American Thoracic Society (ATS) Annual Meeting. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed and engine...

Yahoo | August 5, 2020

Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that second quarter 2020 financial results will be reported on Monday, August 10, 2020. The company will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7295403. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.About LiquidiaLiquidia is a late-s...

Yahoo | August 3, 2020

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent

RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics Corporation (UTC) filed an amended complaint in its patent infringement action under the Hatch-Waxman Act against the Company in the U.S. District Court for the District of Delaware. The amended complaint asserts infringement of an additional recently issued U.S. Patent No. 10,716,793 (‘793) allegedly relating to UTC’s Tyvaso®, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH). The lawsuit was originally filed in June 2020 in response to Li...

Yahoo | July 24, 2020

SHAREHOLDER ALERT: Halper Sadeh LLP Announces It is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:

Yahoo | July 9, 2020

Liquidia Announces Closing of Public Offering of Common Stock

Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. All of the shares in the offering were sold by Liquidia. In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less the underwriting discount and commissions.

Yahoo | July 2, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5471 seconds.